Exenatide combined with metformin had more differential metabolites compared to metformin alone, acting positively and effectively on the HPO and its bypass, improving amino acid, glucose, and lipid metabolism directly or indirectly, thereby inhibiting androgen synthesis, improving insulin resistance, and other metabolic syndromes in obese PCOS patients. The gene discussed is GFER; the disease is polycystic ovary syndrome.